Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-02-08, Stock:ABBV, The news for the past five days is as follows:
2018-02-01: NEWS1: Top 4 Marijuana Stocks to Watch.NEWS2: 5 Best Performing Stocks of January.NEWS3: 5 Best Performing Stocks of January.NEWS4: A Look at Analysts’ Estimates for Johnson & Johnson.NEWS5: Will Gilead (GILD) Disappoint Investors in Q4 Earnings?.NEWS6: Will Gilead (GILD) Disappoint Investors in Q4 Earnings?.NEWS7: Merck’s 4Q17 Estimates: Animal Health.NEWS8: Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi.NEWS9: Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi.NEWS10: Will Gilead (GILD) Disappoint Investors in Q4 Earnings?.NEWS11: Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi.NEWS12: Wired News – Shire Secured Exclusive Worldwide License to Develop and Commercialize AB Biosciences’ PRIM Program.NEWS13: Cramer Remix: Here are the best-in-show biotechs for 2018....NEWS14: Cramer Remix: AbbVie and Biogen are the best-in-show biotechs for 2018 so far.
2018-02-02: NEWS1: Amgen (AMGN) Q4 Earnings & Sales Lag, 2018 Sales View Soft.NEWS2: Amgen (AMGN) Q4 Earnings & Sales Lag, 2018 Sales View Soft.NEWS3: 5 Top Earnings Growth Stocks to Buy in February.NEWS4: 5 Top Earnings Growth Stocks to Buy in February.NEWS5: AstraZeneca (AZN) Beats on Q4 Earnings, Guides for 2018.NEWS6: Gilead's (GILD) HCV Segment to Decline Further in Q4 Earnings?.NEWS7: Gilead's (GILD) HCV Segment to Decline Further in Q4 Earnings?.NEWS8: 5 Top Earnings Growth Stocks to Buy in February.NEWS9: The Best Dividend Reinvestment Plans For 2018.NEWS10: Look Beyond Pharma to Invest in Marijuana Industry.NEWS11: 3 Top Biotherapeutics Stocks to Buy Now.NEWS12: 3 Top Biotherapeutics Stocks to Buy Now.NEWS13: 3 Top Biotherapeutics Stocks to Buy Now.
2018-02-05: NEWS1: Bristol-Myers (BMY) Beats on Q4 Earnings, Eliquis Impresses.NEWS2: Bristol-Myers (BMY) Beats on Q4 Earnings, Eliquis Impresses.NEWS3: Bristol-Myers (BMY) Beats on Q4 Earnings, Eliquis Impresses.NEWS4: The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex.NEWS5: The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex.NEWS6: 3 Top Pharmaceutical Stocks to Buy Now.NEWS7: 3 Top Pharmaceutical Stocks to Buy Now.NEWS8: The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex.NEWS9: 3 Top Pharmaceutical Stocks to Buy Now.NEWS10: How Is Big Business Using the Trump Tax Cut? What We Know So Far.
2018-02-06: NEWS1: AbbVie Has Raised Its 2018 Earnings Guidance.NEWS2: Notable ETF Inflow Detected - MTUM, BA, ABBV, PYPL.NEWS3: Notable ETF Inflow Detected - MTUM, BA, ABBV, PYPL.NEWS4: Centene (CNC) Beats Q4 Earnings & Revenues, Ups '18 View.NEWS5: Centene (CNC) Beats Q4 Earnings & Revenues, Ups '18 View.NEWS6: Analysts’ Recommendations for AbbVie and Peers in January 2018.NEWS7: AbbVie's Imbruvica Gains 'Orphan Drug' Status.NEWS8: Centene (CNC) Beats Q4 Earnings & Revenues, Ups &apos;18 View.NEWS9: Free Post Earnings Research Report: AbbVie’s Q4 FY17 Results Beat Market Estimates.
2018-02-07: NEWS1: Wednesday's ETF with Unusual Volume: PPH.NEWS2: Wednesday's ETF with Unusual Volume: PPH.NEWS3: Add These 7 GARP Stocks to Your Portfolio for Better Returns.NEWS4: Add These 7 GARP Stocks to Your Portfolio for Better Returns.NEWS5: Humira Will Remain a Key Growth Driver for AbbVie in 2018.NEWS6: Gilead (GILD) Beats on Q4 Earnings, 2018 View Lacks Lustre.NEWS7: Gilead (GILD) Beats on Q4 Earnings, 2018 View Lacks Lustre.NEWS8: Add These 7 GARP Stocks to Your Portfolio for Better Returns.NEWS9: Why AbbVie Inc.'s Shares Rocketed 16% in January.NEWS10: Why AbbVie Inc.'s Shares Rocketed 16% in January.NEWS11: AbbVie Expected to Witness Strong Growth in Margins in 2018.NEWS12: Gilead Sciences Inc. Delivers Deja Vu in the Fourth Quarter.NEWS13: Gilead Sciences Inc. Delivers Deja Vu in the Fourth Quarter.NEWS14: Why AbbVie is a Top 25 Dividend Giant (ABBV).NEWS15: Why AbbVie is a Top 25 Dividend Giant (ABBV).NEWS16: Why AbbVie Inc.&apos;s Shares Rocketed 16% in January.NEWS17: Tax Cuts and Jobs Act Has Proven a Major Boon for AbbVie in 2018.NEWS18: New Research: Key Drivers of Growth for Rockwell Automation, Voya Financial, EPR Properties, Hudson Pacific Properties, AbbVie, and Ventas — Factors of Influence, Major Initiatives and Sustained Production.

Answer: Decrease